Review of quetiapine and its clinical applications in schizophrenia

10.1001/archpsyc.1994.03950010008002

GUNDERSON JG, 1973, Am. J. Psychiatry, 132, 901

CALDWELL CB, 1990, Schizophr. Bull., 16, 371, 10.1093/schbul/16.4.571

10.1126/science.3854

10.1001/archpsyc.1964.01720210096015

JIBSON MD AND TANDON R, 1995, Directions Psychiatry, 15, 1

BILDER RM, 1997, Can. J. Psychiatry, 42, 255, 10.1177/070674379704200303

10.1001/archpsyc.1990.01810220065008

10.1097/00005053-198208000-00004

ABI-DARGHAM A, 1997, J. Neuropsychiatry Clin. Neurosci., 9, 1, 10.1176/jnp.9.1.1

KAPUR S, 1996, Am. J. Psychiatry, 153, 466, 10.1176/ajp.153.4.466

AMSLER HA, 1977, A study of the Finnish epidemic. Acta. Psychiatr. Scand., 56, 241, 10.1111/j.1600-0447.1977.tb00224.x

10.1001/archpsyc.1988.01800330013001

JIBSON MD, 1998, J. Psychiatr. Res., 32, 213, 10.1016/S0022-3956(98)00023-5

ARVANITIS LA, 1997, The Seroquel Trial 13 Study Group. Biol. Psychiatry, 42, 233

10.1097/00004714-199902000-00011

BEASLEY CM, 1997, Eur. Neuropsychopharmacol., 7, 125, 10.1016/S0924-977X(96)00392-6

SMALL JG, 1997, A high-and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch. Gen. Psychiatry, 54, 549

SALLER F, 1993, Psychopharmacology, 112, 283, 10.1007/BF02244923

GOLDSTEIN J, 1995, Review of preclinical pharmacology and highlights of Phase II clinical trials. CNS Drug Reviews, 1, 50

MIGLER BM, 1993, Psychopharmacology, 122, 299, 10.1007/BF02244925

ELLENBROEK BA, 1996, Neuropsychopharmacology, 15, 406, 10.1016/0893-133X(96)00001-2

10.1515/REVNEURO.1999.10.1.59

KUFFERLE B, 1997, Psychopharmacology, 133, 323, 10.1007/s002130050409

10.1007/BF02244924

ROBERTSON GS, 1994, J. Pharmacol. Exp. Ther., 271, 1058

VAHID-ANSARI F, 1996, Eur. J. Neurosci., 8, 927, 10.1111/j.1460-9568.1996.tb01579.x

VAHID-ANSARI F, 1996, Eur. J. Neurosci., 8, 2605, 10.1111/j.1460-9568.1996.tb01555.x

CAREY GJ, 1997, Psycho-pharmacology, 132, 261, 10.1007/s002130050344

WONG JYW, EWING BJ, THYRUM PT, YEH C, 1997, Schizophrenia Res., 24, 199

WONG JYW, EWING BJ, THYRUM PT, YEH C, 1997, Schizophrenia Res., 24, 200

10.1097/00004714-199604000-00008

10.1111/j.1600-0447.1997.tb10162.x

COPOLOV DL LINK CGG, 2000, Psychol. Med., 30, 95, 10.1017/S0033291799001476

BEASLEY CM, 1996, Psychopharmacology, 124, 159, 10.1007/BF02245617

TOLLEFSON GD, 1997, Am. J. Psychiatry, 154, 1248, 10.1176/ajp.154.9.1248

10.1097/00004714-199710000-00010

10.1176/ajp.151.6.825

10.1097/00004714-199302000-00004

BLIN, 1996, J. Clin. Psychopharmacol., 16, 38, 10.1097/00004714-199602000-00007

BEASLEY CM, 1996, Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology, 14, 111

EMSLEY RA, 2000, Int. Clin. Psychopharmacol ., 15, 121, 10.1097/00004850-200015030-00001

RAK I, 2000, Schizophrenia Res., 41, B74

DRAKE RE, 1985, Am. J. Psychiatry, 142, 499, 10.1176/ajp.142.4.499

BELLUS SB, 1995, Psychiatr. Serv., 46, 187, 10.1176/ps.46.2.187

SETH A, 1994, J. Clin. Psychiatry, 55, 440

PURDON S, 2000, Schizophrenia Res., 41, B82

10.1001/archpsyc.1991.01810310036007

10.1037/0021-843X.98.4.367

SAX KW, 1998, Schizophrenia Res., 33, 151, 10.1016/S0920-9964(98)00067-X

FLEMING K, 1997, Schizophrenia Res, 24, 197, 10.1016/S0920-9964(97)82564-9

10.4088/JCP.v60n0504

BARNES TRE, BRAUDE WM, 1985, Arch. Gen. Psychiatry, 42, 874, 10.1001/archpsyc.1985.01790320042006

BURKE RE, 1989, Mov. Disord., 4, 157, 10.1002/mds.870040208

KLAWANS HI, 1980, Am . J . Psychiatry, 137, 900, 10.1176/ajp.137.8.900

GLAZER WM, 2000, Schizophrenia Res., 41, B45, 10.1016/S0920-9964(00)90811-9

PEUSKENS J, 1998, Clear Perspectives, 1, 17

GOLDSTEIN JM, ARVANITIS LA, CANTILLON M: Low incidence of reproductive/hormonal side effects with 'Seroquel' (quetiapine fumarate) is supported by its lack of elevation of plasma prolactin concentrations. 36th Annual Meeting of the American College of Neuropsy-chology. Waikoloa, Hawaii, USA (1997).

MEATS P, 1997, Int. J. Psychiatry Clin. Pract., 1, 231, 10.3109/13651509709024734

GUNASEKARA NS, 1998, a review of its use in schizophrenia. CNS Drugs, 9, 325

ALLISON DB, 1999, Am. J. Psychiatry, 156, 1686, 10.1176/ajp.156.11.1686

JONES AM, 2000, Schizophrenia Res., 41, B83

BRECHER M, 1997, Psychopharmacol., 17, 435, 10.1097/00004714-199710000-00022

KALALI A, 1999, Curr. Med. Res. opin., 15, 135, 10.1185/03007999909113374

HELLEWELL JSE, KALALI AH, LANGHAM SJ, MCKELLAR J, AWAD AG, 1999, Intl Psych. Clin. Pract., 3, 105, 10.3109/13651509909024770